Navigation Links
Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
Date:6/6/2008

RESEARCH TRIANGLE PARK, N.C., June 6 /PRNewswire/ -- Quintiles Transnational Corp. today announced the appointment of Christopher H. Cabell, M.D., MHS, FACC, as Chief Medical and Scientific Officer. Cabell succeeds Oren Cohen, M.D., who was recently appointed Senior Vice President, Clinical Research Strategies.

As Chief Medical and Scientific Officer, Cabell will be responsible for company-wide initiatives that focus on bioethics and the protection of human subjects. In addition, he will be responsible for developing initiatives that bring forward innovations in medicine, science and technology into future business models.

Most recently, Cabell held the position of Global Cardiovascular / Endocrine Therapeutic Group Leader within the Medical and Scientific Services group and provided cardiology expertise for Quintiles Electrocardiogram (ECG) Services. In 2007, Cabell joined Quintiles from the Duke University School of Medicine, where he developed a strong background in clinical research. He held several appointments within the Duke Clinical Research Institute (DCRI), including Co-Chair and Principal Investigator for a Duke/FDA Cardiac Safety partnership to develop a new generation of tools to identify the potential effects of medical devices and drugs on the heart. Also within DCRI, he held appointments as Director of the Echocardiography Core Laboratory, Associate Director of the ECG Core Laboratory and Director of the International Collaboration on Endocarditis. He also was Assistant Professor of Medicine in the Division of Cardiology.

Cabell has authored or co-authored 50 articles for peer-reviewed publications and delivered more than 30 invited lectures. He is a member of several professional organizations, a Fellow of the American College of Cardiology, and a reviewer for a number of medical journals, including the Journal of the American Medical Association. He earned his medical degree and a Master's in Health Science from the Duke University School of Medicine.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, commercialization and strategic partnering for the pharmaceutical, biotechnology and medical device industries. With more than 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at http://www.qtrn.com


'/>"/>
SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Expert Cardiologist Joins Quintiles Medical Group
3. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
4. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
5. Quintiles to Open Clinical Research Office in Wilmington, NC
6. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
7. Quintiles Consulting Business Expands
8. Quintiles Signs Agreement to Acquire Eidetics
9. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
10. Codexis Appoints Singapore Laboratories Managing Director
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):